Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells

Journal of Investigative Dermatology

Volumn 132, Issue 2, 2012, Pages 324-329

  Asadi, Shahrzad ^a,b   Alysandratos, Konstantinos Dionysios ^a,c,e   Angelidou, Asimenia ^a,c,e   Miniati, Alexandra ^a   Sismanopoulos, Nikolaos ^a,c   Vasiadi, Magdalini ^a,c,d   Zhang, Bodi ^a,d   Kalogeromitros, Dimitrios ^c   Theoharides, Theoharis C ^a,c,d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d TUFTS UNIVERSITY   (United States)

^e SOUTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; INTERLEUKIN 8; MESSENGER RNA; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MAST CELL LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PSORIASIS; UPREGULATION;

EID: 84855918920     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.334     Document Type: Article

References (65)

1. Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10:440-52
2. Agelaki S, Tsatsanis C, Gravanis A et al. (2002) Corticotropin-releasing hormone augments proinflammatory cytokine production from macro-phages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun 70:6068-74 (Pubitemid 35192696)
3. Agren G, Milsson K, Ronquist G (1976) A Mg2+ and Ca2+-stimulated ATPase at the outer surface of human peripheral leucocytes and hymatopoietic cell lines. Correlation between enzyme activity and immunoglobulin secretion. Acta Physiol Scand 98:67-73
4. Al'Abadie MS, Senior HJ, Bleehen SS et al. (1995) Neuropeptides and general neuronal marker in psoriasis-an immunohistochemical study. Clin Exp Dermatol 20:384-9 (Pubitemid 26007595)
5. Arck PC, Handjiski B, Kuhlmei A et al. (2005) Mast cell deficient and neurokinin-1 receptor knockout mice are protected from stress-induced hair growth inhibition. J Mol Med 83:386-96 (Pubitemid 41201803)
6. Barile S, Medda E, Nistico L et al. (2006) Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. Exp Dermatol 15:368-76 (Pubitemid 44056484)
7. Boesiger J, Tsai M, Maurer M et al. (1998) Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fce receptor I expression. J Exp Med 188:1135-45 (Pubitemid 28443337)
8. Boucher W, Kempuraj D, Michaelian M et al. (2010) Corticotropin-releasing hormone-receptor 2 is required for acute stress-induced bladder vascular permeability and release of vascular endothelial growth factor. BJU Int 106:1394-9
9. Cao J, Papadopoulou N, Kempuraj D et al. (2005) Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 174:7665-75 (Pubitemid 40806271)
10. Carraway R, Leeman SE (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248:6854-61
11. Chan J, Smoller BR, Raychauduri SP et al. (1997) Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 289:611-6 (Pubitemid 27510824)
12. Chen R, Lewis KA, Perrin MH et al. (1993) Expression cloning of a human corticotropin-releasing factor receptor. Proc Natl Acad Sci USA 90:8967-71 (Pubitemid 23306432)
13. Chrousos GP (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332:1351-62
14. Creamer D, Allen M, Jaggar R et al. (2002) Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 138:791-6 (Pubitemid 34625524)
15. Detmar M (2004) Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J Invest Dermatol 122:209-15
16. Farber EM, Nickoloff BJ, Recht B et al. (1986) Stress, symmetry, and psoriasis: possible role of neuropeptides. J Am Acad Dermatol 14:305-11
17. Fewtrell CMS, Foreman JC, Jordan CC et al. (1982) The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J Physiol 330:393-411 (Pubitemid 12024576)
18. Florio P, Franchini A, Reis FM et al. (2000) Human placenta, chorion, amnion and decidua express different variants of corticotropin-releasing factor receptor messenger RNA. Placenta 21:32-7 (Pubitemid 30099492)
19. Fortune DG, Richards HL, Griffiths CE (2005) Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 23:681-94 (Pubitemid 41169842)
20. Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6:135-42 (Pubitemid 40268194)
21. Grammatopoulos DK (2008) Placental corticotrophin-releasing hormone and its receptors in human pregnancy and labour: still a scientific enigma. J Neuroendocrinol 20:432-8
22. Grutzkau A, Kruger-Krasagakes S, Baumeister H et al. (1998) Synthesis, storage and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell 9:875-84 (Pubitemid 28173640)
23. Hamke M, Herpfer I, Lieb K et al. (2006) Substance P induces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor. Brain Res 1102:135-44 (Pubitemid 44092658)
24. Harvima IT, Viinamäki H, Naukkarinen A et al. (1993) Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother Psychosom 60:168-76 (Pubitemid 23323744)
25. Harvima RJ, Viinamäki H, Harvima IT et al. (1996) Association of psychic stress with clinical severity and symptoms of psoriatic patients. Acta Derm Venereol (Stockh) 76:467-71 (Pubitemid 26398097)
26. Heidenreich R, Rocken M, Ghoreschi K (2009) Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 90:232-48
27. Huang M, Kempuraj D, Papadopoulou N et al. (2009) Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-kappaB activation. J Mol Endocrinol 42:397-405
28. Jiang WY, Raychaudhuri SP, Farber EM (1998) Double-labeled immuno-fluorescence study of cutaneous nerves in psoriasis. Int J Dermatol 37:572-4 (Pubitemid 28389315)
29. Karalis K, Sano H, Redwine J et al. (1991) Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254:421-3 (Pubitemid 21917357)
30. Katsarou-Katsari A, Singh LK, Theoharides TC (2001) Alopecia areata and affected skin CRH receptor upregulation induced by acute emotional stress. Dermatology 203:157-61 (Pubitemid 34701577)
31. Kawana S, Liang Z, Nagano M et al. (2006) Role of substance P in stress-derived degranulation of dermal mast cells in mice. J Dermatol Sci 42:47-54 (Pubitemid 43384129)
32. Kempuraj D, Papadopoulou NG, Lytinas M et al. (2004) Corticotropin- releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 145:43-8 (Pubitemid 38094499)
33. Liaw CW, Lovenberg TW, Barry G et al. (1996) Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 137:72-7
34. McCary C, Tancowny BP, Catalli A et al. (2010) Substance P downregulates expression of the high affinity IgE receptor (FcepsilonRI) by human mast cells. J Neuroimmunol 220:17-24
35. Naukkarinen A, Jarvikallio A, Lakkakorpi J et al. (1996) Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J Pathol 180:200-5 (Pubitemid 26370188)
36. O'Connor TM, O'Connell J, O'Brien DI et al. (2004) The role of substance P in inflammatory disease. J Cell Physiol 201:167-80 (Pubitemid 39305095)
37. Ö zdamar SO, Seckin D, Kandemir B et al. (1996) Mast cells in psoriasis. Dermatology 192, 190.
38. Papadopoulou N, Kalogeromitros D, Staurianeas NG et al. (2005a) Corticotropin-releasing hormone receptor-1 and histidine decarboxylase expression in chronic urticaria. J Invest Dermatol 125:952-5
39. Papadopoulou NG, Oleson L, Kempuraj D et al. (2005b) Regulation of corticotropin-releasing hormone receptor-2 expression in human cord blood-derived cultured mast cells. J Mol Endocrinol 35:R1-8 (Pubitemid 43025581)
40. Paus R, Heinzelmann T, Robicsek S et al. (1995) Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation in situ. Arch Dermatol Res 287:500-2
41. Paus R, Maurer M, Slominski A et al. (1994) Mast cell involvement in murine hair growth. Dev Biol 163:230-40 (Pubitemid 24188887)
42. Paus R, Theoharides TC, Arck P (2006) Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol 27:32-9
43. Peters EM, Kuhlmei A, Tobin DJ et al. (2005) Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin. Brain Behav Immun 19:252-62 (Pubitemid 40431540)
44. Remröd C, Lonne-Rahm S, Nordliond K (2007) Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res 299:85-91 (Pubitemid 46669413)
45. Simonetti O, Lucarini G, Goteri G et al. (2006) VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol 19:751-60 (Pubitemid 46145039)
46. Slominski A (2009) On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders. Br J Dermatol 160:229-32
47. Slominski A, Pisarchik A, Tobin DJ et al. (2004) Differential expression of a cutaneous corticotropin-releasing hormone system. Endocrinology 145:941-50 (Pubitemid 38183838)
48. Slominski A, Wortsman J (2000) Neuroendocrinology of the skin. Endocr Rev 21:457-87
49. Slominski A, Wortsman J, Luger T et al. (2000) Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 80:979-1020 (Pubitemid 30452009)
50. Slominski A, Wortsman J, Tuckey RC et al. (2007) Differential expression of HPA axis homolog in the skin. Mol Cell Endocrinol 265-266:143-9 (Pubitemid 46273958)
51. Tagen M, Elorza A, Kempuraj D et al. (2009) Mitochondrial uncoupling protein 2 inhibits mast cell activation and reduces histamine content. J Immunol 183:6313-9
52. Tagen M, Stiles L, Kalogeromitros D et al. (2007) Skin corticotropin-releasing hormone receptor expression in psoriasis. J Invest Dermatol 127:1789-91 (Pubitemid 46933407)
53. Theoharides TC, Cochrane DE (2004) Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 146:1-12 (Pubitemid 38032950)
54. Theoharides TC, Donelan JM, Papadopoulou N et al. (2004) Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 25:563-8 (Pubitemid 39371146)
55. Theoharides TC, Kalogeromitros D (2006) The critical role of mast cell in allergy and inflammation. Ann NY Acad Sci 1088:78-99 (Pubitemid 47092046)
56. Theoharides TC, Singh LK, Boucher W et al. (1998) Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology 139:403-13 (Pubitemid 28166335)
57. Theoharides TC, Zhang B, Kempuraj D et al. (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107:4448-53
58. Tsatsanis C, Androulidaki A, Dermitzaki E et al. (2007) Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2. J Cell Physiol 210:774-83 (Pubitemid 46185047)
59. Tuluc F, Lai JP, Kilpatrick LE et al. (2009) Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol 30:271-6
60. Xia YP, Li B, Hylton D et al. (2003) Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102:161-8 (Pubitemid 36759650)
61. Yalcin B, Tezel GG, Arda N et al. (2007) Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis. Anal Quant Cytol Histol 29:358-64 (Pubitemid 350304993)
62. Zbytek B, Pfeffer LM, Slominski AT (2004) Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes. J Endocrinol 181:R1-7 (Pubitemid 38868204)
63. Zbytek B, Pikula M, Slominski RM et al. (2005) Corticotropin-releasing hormone triggers differentiation in HaCaT keratinocytes 1. Br J Dermatol 152:474-80 (Pubitemid 40547121)
64. Zbytek B, Slominski AT (2007) CRH mediates inflammation induced by lipopolysaccharide in human adult epidermal keratinocytes. J Invest Dermatol 127:730-2
65. Zhang Y, Matsuo H, Morita E (2005) Vascular endothelial growth factor 121 is the predominant isoform in psoriatic scales. Exp Dermatol 14:758-64 (Pubitemid 41419463)